



triazolo[4,3-a)[1,4]diazepine) is a lipophilic platelet-
activating factor (PAF) antagonist. In the present study,
we incorporated Y-24180 into lipid microspheres (LM)
and its activity was evaluated in vivo. When Lipo 
Y-24180 was intravenously given 3 min before PAF
injection, the maximal bronchoconstriction was reduced.
The mean (±SEM) PAF-induced respiratory flow resis-
tance in Lipo Y-24180 (1 m g/kg)-treated animals at
0.5 min was 19.0 ± 8.0%, which was significantly
lower than that of the vehicle-treated control (61.5 ±
13.0%; P < 0.05). Three and 10 m g/kg Lipo Y-24180
almost completely inhibited the respiratory flow resis-
tance. Alone, Y-24180 dose-dependently suppressed
the bronchoconstriction; however, a significant decrease
was only seen in 10 m g/kg-treated animals. There
were also significant differences between the Lipo 
Y-24180 (1 m g/kg)-treated group and Y-24180 (1 and
3 mg/kg) treated groups. Aerosol inhalation of Lipo 
Y-24180 (10 m g/mL) caused no significant suppres-
sion; however, a significant inhibition was observed 
in guinea pigs that were administered more than 
30 m g/mL. Therefore, it would be concluded that Lipo
Y-24180 would have a potency as a bronchodilator
and would be promising as both an injectable drug
and an inhaler.
Key words: bronchoconstriction, inhaler, intravenous
treatment, lipid microspheres, platelet-activating fac-
tor antagonist, Y-24180.
INTRODUCTION
Platelet-activating factor (PAF) is involved in various physi-
ological and pathophysiological events, such as broncho-
constriction, chemotaxis, airway secretion, microvascular
leakage and bronchial hyperreactivity. These effects may
be relevant to asthma and, therefore, it has been sug-
gested that selective antagonists of PAF may be beneficial
for the treatment of asthma and bronchial hyperreactivity.
(±)-4-(2-Chloro-phenyl)-2-[2-(4-isobuthylphenyl)ethyl]
6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3(a)[1,4]
diazepine (Y-24180; Fig. 1) is one of the most potent 
PAF antagonists1,2 and also possess lipophilic properties.
Lipid microspheres (LM; Fig. 1) are used as nutrients in
the clinical setting and are drug carriers for lipophilic
agents.3,4 Lipid microspheres consist of soybean oil and
egg yolk lecithin, have a diameter of 0.2–0.3 m m and
preferentially accumulate in inflammatory lesions. Elect-
ron microscopic studies have revealed that LM are taken
up by endocytosis into activated inflammatory cells, such
as macrophages, neutrophils, vascular endothelial cells,
and tumor cells in vitro.5,6 It has also been confirmed that
LM given intravenously to spontaneously hypertensive
rats (SHR) penetrated through endothelial cell gaps in
aortic intimal lesions and accumulated in the suben-
dothelial space.7 Further in vivo studies in humans have
demonstrated that 99mTc-labeled LM administered intra-
venously to patients with arteriosclerosis obliterans (ASO)
or rheumatoid arthritis (RA) accumulated in the reticu-
loendothelial system (including the liver and spleen) and
in the inflammatory lesions of RA patients.8 In fact, LM
containing prostaglandin (PG)E1 have been used in the
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clinical setting and have made a contribution to improv-
ing the condition of patients with several peripheral
vascular diseases etc. This can be explained by the evi-
dence that LM deliver drugs towards inflammatory sites.
Lipid microsphere-incorporated agents need higher
lipophilicity, because they are dissolved in soybean oil. If
not, their fate would not be the same as that of LM, and an
excellent pharmacological effect could not be obtained
in vivo.9–11 From this point of view, lipophilic Y-24180 
can be a good candidate for incorporating drugs into
LM. So, we prepared Y-24180-encapsulated LM (Lipo 
Y-24180) and assessed its effect in vivo.
The aim of the present study was to evaluate the 
possibility of Lipo Y-24180 as a bronchodilator. Lipo 
Y-24180 can be not only an injectable drug but also an
inhaler. In particular, the respiratory area is one of the
attractive drug delivery routes, because of the convenience
and the ability to absorb various drugs. Previously, we have
shown12 that aerolized LM-encapsulated PGE1 could delay
the onset and decrease the severity of dyspnea as well as
reducing bronchial irritation when compared with free
PGE1 in animals and in asthmatics. Also, we have demon-
strated13 that inhalation of LM-encapsulated drug led to
markedly enhanced pulmonary accumulation, and its in
vitro uptake by human eosinophils and neutrophils was
higher than that of unencapsulated drug. Therefore,
aerosol administration would be a desirable method in
order to not only be more convenient but also to lower the
required dose for the treatment of asthma etc.
METHODS
Reagents
Y-24180 was kindly provided by WelFide Corporation
(Osaka, Japan).
Platelet-activating factor was purchased from Bachem
Fine Chemicals (AG, Bubendorf, Switzerland).
Animals
Female Hartley guinea pigs (Nihon Ikagaku, Saitama,
Japan) weighing 350–400 g were used. Animals were
housed at a constant temperature (23 ± 1°C) and
humidity (50–60%) with free access to a standard diet
and water. The animal room had a 12 h light/dark cycle
(lights on 06.30–18.30 h).
The protocol of the present study was approved by the
animal experimentation committees of St Marianna
University.
Preparation of Lipo Y-24180
Lipid microspheres containing Y-24180 (Lipo Y-24180)
were prepared as described previously.13 Briefly, 10 mg 
Y-24180 was dissolved in 1 g soybean oil and mixed with
120 mg yolk lecithin. The mixture was then poured into a
2.58% glycerol aqueous solution with agitation to make
a 10% (w/v) oil-in-water suspension. Subsequently, the
mixture was emulsified using a French pressure homoge-
nizer (SLM Instruments Inc., Urbana, IL, USA) to yield a
144 M TAKENAGA ET AL.
Fig. 1 (a) Structure of Y-24180
and (b) schema of lipid micro-
spheres (LM). Y-24180 (10 mg
or 20 mg) can be easily dissolved
in 1 g soybean oil. Encapsulated
Y-24180 would exist in soybean
oil in the LM.
final concentration of 1 mg/mL. The resultant emulsion
was placed in a sterilized glass ampoule under nitrogen
gas and stored at room temperature until use. Lipid
microsphere preparations were also kept at 4 and 40°C.
The particle size of the LM emulsion was measured by a
Coulter N4 particle analyzer (Coulter, Hialeah, FL, USA).
The amounts of Y-24180 were determined by reverse-
phase high-pressure liquid chromatography (HPLC) using a
Simadzu LC-8 A chromatograph (Kyoto, Japan) equipped
with an ODS column (STR-ODS 5 m m; 7.2 mm · 150 mm;
Hewlett Packard Company, Meriden, CT, USA) with a
solvent system of methanol/10 mmol/L sodium phosphate
buffer pH 6.9 (4 : 1, v/v) as a mobile phase. The flow rate
was 1.0 mL/min. The absorbance of the column eluant at
305 nm was continuously monitored with a UV spectro-
photometer (SPD-6AV; Shimadzu Corporation, Kyoto,
Japan). The column (CTO-6A; Shimadzu Corporation)
temperature was maintained at 40°C. Under these con-
ditions, its retention time was approximately 2.3 min. The
determination of Y-24180 in LM was performed after
extraction by the addition of 10 volumes of methanol.
Induction of bronchoconstriction and 
measurement of respiratory flow resistance 
in guinea pigs
Bronchoconstriction was induced by the injection of PAF.
Platelet-activating factor was administered intravenously
via an ear vein. Respiratory flow resistance (Rrs) was 
measured using conscious animals according to the
method of Mead.14 A type PMR-2 apparatus (Shizume
Medical Co. Ltd, Tokyo, Japan) was used. The animal
chamber consisted of a plastic cylinder with a square
plastic lid. The speaker in the chamber was controlled by
an oscillator connected to an amplifier in order to create
an oscillating pressure of over 10 cm H2O delivered as a
6–20 Hz sine wave.
The mask used for measuring air flow was a plastic
cone fitted closely to the animal’s face. At the top of the
mask, there was a small opening of 8 mm diameter with
a 400 mesh screen. Flow through this screen during
breathing was measured with a pressure transducer as the
pressure difference between the interior of the mask and
the room. The pressure in the chamber and the air flow
through the mask were monitored with a differential trans-
ducer and the signal was transferred to an oscilloscope
after amplification by a carrier amplifier. The Rrs was then
obtained as the ratio of air flow and chamber pressure.
A stock solution of PAF was made up in ethanol and
stored at – 20°C. This solution was diluted in physio-
logical saline before use.
Administration of Lipo Y-24180
Lipo Y-24180 was administered by the intravenous route or
aerosol inhalation. Intravenous injection was performed
through the ear vein 3 min prior to PAF injection. Aerosol
administration of drugs was performed10 for 2 min with 
a Devilbiss Pulmo-Aide 646 compressed-air nebulizer
(Somerset, PA, USA) at a flow rate of 6 L/min (2.6 kg/cm2).
The mean diameter of the aerosol particles produced by
the nebulizer is considered to be approximately 3 m m.
Aerosol administration of Lipo Y-24180 was done to indi-
vidual animals via nose breathing from a starting volume
of 5 mL. The time required to nebulize the total volume of
solution was approximately 35–45 min when LM without
drug was used. All aerosol inhalation experiments were
performed in a room equipped with ventilation apparatus
and maintained at a constant relative humidity (50–60%)
and temperature (20–25°C).
Statistical analysis
Statistical analysis was performed with the Mann–Whitney
U-test and P < 0.05 was taken to indicate significance.
RESULTS
Lipid microspheres containing Y-24180
Ten or 20 mg Y-24180 was so easily dissolved in 1 g of
soybean oil that we could finally yield 1 or 2 mg/mL of 
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Table 1 Particle size of lipid microsphere-encapsulated Y-24180
Concentration Temperature Particle size (nm)
(mg/mL) (°C) Time 0 1 week 2 weeks 3 weeks 4 weeks
1 4 216 ± 34 221 ± 26 223 ± 26 225 ± 26 220 ± 26
40 218 ± 27 237 ± 66 234 ± 56 222 ± 26
2 4 215 ± 32 238 ± 57 224 ± 26 222 ± 26 220 ± 26
40 231 ± 46 219 ± 27 217 ± 28 236 ± 42
The particle size (mean ± SD) of the lipid microsphere emulsion was measured by a Coulter N4 particle analyzer.
Y-24180-incorporated LM (Lipo Y-24180). The mean
size of the LM (1 mg/mL) was 216 ± 34 nm (Table 1).
When this formulation was kept at 4 or 40°C, there was
little change in size, even at 40°C. The definite size of the
particles was maintained for at least 3 months. Similar
results were also obtained for approximately 2 mg/mL
Lipo Y-24180.
The content of Y-24180 in LM was also determined by
HPLC. After 1 month, 98.7% of Y-24180 existed at 4°C.
In addition, it was found that 92.9% of this compound
remained unchanged at 40°C.
Inhibition of PAF-induced bronchoconstriction
by Lipo Y-24180
Platelet-activating factor (0.03–1 m g/kg) produced a
dose-related bronchoconstriction that peaked at 0.5 or 
1 min (data not shown). Above 60% maximal broncho-
constriction was induced by PAF (0.15 m g/kg) injection,
when the baseline was considered as 0%. Therefore, the
dose of 0.15 m g/kg was chosen for evaluating the drug
effects.
Intravenous effects of Lipo Y-24180 were first exam-
ined. The PAF caused a mean (± SEM) maximal
bronchoconstriction of 61.5 ± 13.0% at 0.5 min (Fig. 2;
Table 2). In addtion, the increase in Rrs was little affected,
even if LM without drug (vehicle for Lipo Y-24180) or
propylene glycol (vehicle for Y-24180) were given i.v.
When Lipo Y-24180 (1, 3 and 10 m g/kg) was adminis-
tered i.v. 3 min prior to PAF injection, the maximal
bronchoconstriction was suppressed. Mean Rrs in Lipo 
Y-24180 (1 m g/kg)-treated animals at 0.5 min was 
19.0 ± 8.0%, which was significantly lower than that of
vehicle-treated controls (P < 0.05). A higher Rrs was
observed at 1 min (27.0 ± 10.0%), which was still lower
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Fig. 2 Intravenous effect of Lipo Y-24180 on platelet-activat-
ing factor (PAF)-elicited bronchoconstriction. Either Lipo
Y-24180 (d) or Y-24180 (n; 1 m g/kg) was given i.v. to guinea
pigs 3 min prior to the PAF (0.15 m g/kg) injection. Data are
expressed as the respiratory flow resistance percentage (Rrs),
for which the baseline was considered 0%. Lipid microspheres
without the drug or propylene glycol was used as the vehicle
(s). Measurements are the mean ± SEM, n = 8. * P < 0.05
compared with the control.
Table 2 Intravenous effect of Y-24180 and lipid microsphere-encapsulated Y-24180 on platelet-activating factor-induced 
bronchoconstriction in guinea pigs
Treatment Respiratory flow resistance (%)
(m g/kg) 0.5 min 1 min 1.5 min 2 min 3 min 4 min 5 min
Vehicle 61.5 ± 13.0 48.3 ± 10.0 26.1 ± 6.0 13.3 ± 5.0 9.3 ± 7.0 4.4 ± 4.0 5.5 ± 1.0
Lipo Y-24180
1 19.0 ± 8.0*† 27.0 ± 10.0 16.0 ± 8.0 13.2 ± 7.0 1.6 ± 5.0 –2.0 ± 5.0 8.8 ± 7.0
3 0.7 ± 5.6** 0.5 ± 3.0** –0.8 ± 5.0** 3.3 ± 3.0 6.3 ± 6.0 9.7 ± 5.0 10.8 ± 5.0
10 –1.8 ± 5.0** 3.0 ± 6.0** 4.0 ± 6.0* 5.6 ± 8.0 8.0 ± 5.0 7.0 ± 4.0 12.0 ± 5.0
Y-24180
1 73.8 ± 17.0 41.5 ± 9.0 52.5 ± 18.0 21.2 ± 16.0 20.3 ± 16.0 8.3 ± 7.0 28.3 ± 16.0
3 94.6 ± 14.0 46.2 ± 18.0 32.0 ± 9.0 32.8 ± 11.0 25.8 ± 18.0 22.4 ± 10.0 23.0 ± 10.0
10 24.0 ± 8.0 15.0 ± 10.0* 14.8 ± 5.0 26.8 ± 2.0* 7.3 ± 2.0 15.3 ± 7.0 15.8 ± 3.0
Data are the mean ± SEM (n = 8). Significant differences were evaluated using the Mann–Whitney U-test. *P < 0.05, **P < 0.01 compared
with vehicle-treated control; †P < 0.05 compared with Y-24180 (1 and 3 m g/kg)-treated control.
Lipid microsphere-encapsulated (Lipo) Y-24180 or Y-24180 was administered intravenously to guinea pigs 3 min prior to injection of platelet-
activating factor. Respiratory flow resistance is expressed as %, where the baseline was considered as 0%.
than that of the control. Three and 10 m g/kg Lipo 
Y-24180 almost completely inhibited the increased Rrs.
Y-24180 (1, 3 and 10 m g/kg) also suppressed PAF-
elicited bronchoconstriction in a dose-dependent manner.
However, significant suppression compared with control
was only seen in 10 m g/kg-treated animals at 1 min. In
addition, in the 1 m g/kg Lipo Y-24180-treated group
there was a significant reduction in PAF-induced broncho-
constriction compared with the 1 and 3 m g/kg Y-24180-
treated groups. Therefore, the potency of 1 m g/kg Lipo 
Y-24180 was estimated to be almost the same as that of
10 m g/kg Y-24180.
The aerosol inhalation effect of Lipo Y-24180 was then
tested. Aerosol inhalation was performed for 2 min and
then PAF was i.v. given to animals. At 0.15 m g/kg, PAF 
produced 66.2 ± 8.0% maximal bronchoconstriction at 
0.5 min after challenge above the baseline (Fig. 3). Less
than 10 m g/mL Lipo Y-24180 caused no significant sup-
pression. The mean Rrs in 10 m g/mL Lipo Y-24180-treated
animals at 0.5 min was 50.1%, which was not significant
compared with control. Maximal bronchoconstriction
was reduced to less than one-half by aerosol exposure to
30 m g/mL Lipo Y-24180 (26.5 ± 9.2%). The aerosol of
Lipo Y-24180 (100 m g/mL) markedly suppressed bron-
choconstriction, as shown in Fig. 3.
DISCUSSION
Platelet-activating factor is a potent proinflammatory 
compound potentially involved in the pathogenesis of
inflammatory disorders, including bronchial asthma, as
reported by Nagase et al.15 They demonstrated that trans-
genic mice overexpressing the PAF receptor showed a
bronchial hyperreactivity to methacholine challenge and
that PAF-induced bronchoconstriction was significantly
attenuated by a PAF receptor antagonist as well as a
thromboxane synthesis inhibitor, an inhibitor of 5-lipoxy-
genase-activating protein and leukotriene antagonist.
A beneficial effect of PAF antagonists on airway hyper-
responsiveness and the late asthmatic response in a guinea
pig model of asthma has been already reported.16,17 Some
PAF antagonists, including Y-24180 are now undergoing
clinical trials.18 Y-24180 has been demonstrated to be a
potent and long-acting PAF antagonist with a high affinity
for the PAF receptor1 and able to reduce PAF-induced
airway hyperresponsiveness19 and allergen-induced air-
way resistance following oral administration in guinea
pigs.2,20 In addition, Y-24180 has been reported to signifi-
cantly improve the provocative concentration-forced
expiratory volume (PC20-FEV1) value of asthmatic patients.21
Furthermore, Mizuki et al.22 have shown that eosinophil
infiltration into the bronchial wall was markedly decreased
in atopic asthmatics after oral administration of Y-24180
and they concluded that Y-24180 inhibited the activation
of eosinophils by antagonizing the actions of PAF in
patients. These in vivo effects of Y-24180 are those
obtained following oral administration, and the effects
following either intravenous administration or inhalation
have not been reported. One reason is that this com-
pound is hard to solubulize because of its lipophilicity.
Our study is the first showing that Y-24180 can be 
incorporated easily into a LM drug carrier and that 
Y-24180-encapsulated LM (Lipo Y-24180) efficiently
suppress PAF-elicited bronchoconstriction following intra-
venous administration and aerosol inhalation.
Lipid microspheres have been used clinically not only as
nutrients, but also an injectable carriers for compounds
such as PGE1, dexamethasone derivatives etc. The reason
why these LM-incorporated drugs are clinically useful is
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Fig. 3 Inhalation effect of Lipo Y-24180 on platelet-activating
factor (PAF)-elicited bronchoconstriction. Lipo Y-24180 was
inhaled by guinea pigs for 2 min, using a nebulizer, prior to the
PAF injection (0.15 m g/kg). Data are expressed as the respira-
tory flow resistance percentage (Rrs), for which the baseline was
considered 0%. Lipid microspheres without the drug was used
as the vehicle (s). Doses of Lipo Y-24180 were 3 (d), 10 (m),
30 (r) or 100 m g/mL (j). *P < 0.05, **P < 0.01 compared
with the control.
because the incorporated drugs are able to be delivered
to the inflammatory sites. Therefore, the antiasthmatic lipo-
philic agent Y-24180 could also be a good candidate for
encapsulated drugs in LM.
The stability of the LM emulsion depends partly on the
solubility of the incorporated compounds.4,9,10,11 There
was no significant change in the size and content of Lipo
Y-24180, even at 40 °C, suggesting that Lipo Y-24180
was stable. This finding also indicates that the fate of 
Y-24180 may be tied together with that of the carrier LM.
Because LM preferentially accumulate in inflammatory
regions and/or cells, higher amounts of Y-24180 may be
also delivered to target sites and/or cells. The evidence
that Lipo Y-24180 inhibited PAF-induced broncho-
constriction more than 10-fold compared with Y-24180
may support this hypothesis.
Furthermore, it is also of note that aerosol inhalation of
Lipo Y-24180 also showed dramatically suppressive
effects on PAF-elicited bronchoconstriction. Y-24180 dis-
solved in propylene glycol was not able to make a fine
aerosol because of its high viscosity. Therefore, it was
impossible to compare its pharmacological potency with
that of Lipo Y-24180 after inhalation. We have already
demonstrated that inhalation of LM-encapsulated drugs
makes the drug accumulate in the pulmonary regions
and the in vitro uptake by human eosinophils and neu-
trophils is higher than that of unencapsulated drugs.10
Because aerosol delivery of drugs would be expected to
achieve higher pulmonary and lower systemic concentra-
tions compared with other routes of administration, such
as oral administration, LM may be valuable drug carriers
for enhancing the pharmacological efficacy of various
antiasthmatic agents, not only PAF antagonists, but also
others.
In conclusion, there is a possibility that lower doses of
Lipo Y-24180 could be much more effective following
both intravenous and aerosol administration.
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